Ophthalmology · Flushing, NY
NPI
1467484071
Since 2006
Specialty
Ophthalmology
Code 207W00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
16110 Union Tpke
Flushing, NY, 11366
Phone (718) 380-5070
Groups this clinician bills Medicare through
Medicare paid, 2024
$28K
322 services
Medicare patients, 2024
105
Average age 77
Drug cost, 2024
$1.1M
5,170 prescriptions
Company payments, 2025
$143
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nancy Cheng was code 92012 (ophthalmological e&m), 96 times for 63 patients. In total Nancy Cheng billed 322 services in 17 codes, and Medicare paid $28K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 92012 Ophthalmological E&M | Office | 96 | 63 | $70.79 | $6,796 |
| 92014 Ophthalmological E&M | Office | 80 | 78 | $92.88 | $7,430 |
| 92133 Computerized Ophthalmic Imaging | Office | 31 | 30 | $29.75 | $922 |
| 92083 Vision, Hearing, and Speech Services | Office | 23 | 23 | $55.54 | $1,277 |
| 92132 Computerized Ophthalmic Imaging | Office | 16 | 16 | $22.26 | $356 |
By year: 2022 $37K for 378 services; 2023 $36K for 333 services; 2024 $28K for 322 services.
Medicare prescription drug claims, 2024
In 2024, the drug Nancy Cheng prescribed most often to Medicare patients was Restasis (Cyclosporine), with 693 prescriptions and refills. In total Nancy Cheng wrote 5,170 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Restasis Cyclosporine | 693 | 770 | 124 | $475K |
| Prednisolone Acetate Generic | 579 | 768 | 259 | $38K |
| Bepotastine Besilate Generic | 544 | 598 | 119 | $66K |
| Latanoprost Generic | 469 | 566 | 64 | $2,873 |
| Timolol Maleate Generic | 384 | 597 | 64 | $15K |
| Azelastine Hcl Generic | 349 | 360 | 91 | $3,627 |
| Besivance Besifloxacin Hcl | 161 | 183 | 125 | $35K |
| Zerviate Cetirizine Hcl | 138 | 143 | 51 | $55K |
| Prolensa Bromfenac Sodium | 134 | 212 | 85 | $45K |
| Erythromycin Erythromycin Base | 129 | 129 | 31 | $1,381 |
| Cyclosporine Generic | 109 | 126 | 30 | $33K |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 104 | 181 | 21 | $1,368 |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 102 | 104 | 74 | $1,099 |
| Combigan Brimonidine Tartrate/Timolol | 99 | 130 | 16 | $29K |
| Alphagan P Brimonidine Tartrate | 97 | 132 | 16 | $27K |
Brand drugs: 2,983 claims; generic drugs: 2,187 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nancy Cheng $143 ($143 in general payments such as food, travel and fees) from 2 companies. The largest payer was Gilead Sciences, Inc. with $125.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.